Glossary
Browse the glossary using this index
Special | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | ALL
T |
---|
Terveyden ja hyvinvoinnin laitosFinnish National Institute for Health and Welfare. https://www.thl.fi" | |
ThalidomideThalidomide is a medicine that was developed in the 1950s as a sedative. It was used later against nausea in pregnant women, but this resulted in the birth of about 10,000 infants with deformed limbs, and sometimes with other serious problems such as blindness, deafness, and heart problems. More than half of these children died. This crisis led to more structured regulations for the development and use of medicines. Currently, thalidomide is used to treat certain cancers, and to alleviate symptoms of leprosy. | ||
Therapeutic AlternativesTherapeutic alternatives are medicines that are chemically different from the one prescribed (used) but which have the same clinical effect. Therapeutic alternatives are not to be confused with generics. | ||
Therapeutic indicationTherapeutic indications are a description of the disease to be treated with a medicine, and the population for which the medicine is intended. They include the specifics about the disease, and restrictions to the patient population such as age, and whether the medicine is intended for symptom relief, cure or prevention, or whether it is for diagnostic use only. Example statements from therapeutic indications:
Therapeutic indications must be clearly and concisely stated within the summary of product characteristics (SmPC) document that each medicine requires in the EU. | ||
Therapeutic vaccinesTherapeutic vaccines introduce antigens associated with an illness to teach the body to fight against a different illness. | ||
Time-to-event endpointA time-to-event endpoint is the time taken until a pre-defined event takes place, once groups in a trial start to receive treatment or placebo. There are several kinds of time-to-event endpoints. For example, time-to-progression (TTP) is the time between randomisation of people to groups within a trial, and disease progression. Disease progression in this case must be defined, and it must be specific and measurable. For example, the growth of a particular tumour type by a minimum amount may be used as an indicator of disease progression. | ||
Time-to-ProgressTime-to-Progress | |
Tissue Engineered Product; Tissue Engineered MedicineTissue Engineered Product; Tissue Engineered Medicine | |
TolerabilityThe tolerability of the medicinal product represents the degree to which adverse effects can be 'tolerated' or accepted by a patient. | ||